Loading
Neon Therapeutics worked on cancer treatments that point the immune system at neoantigens, the changed proteins found only on a person's cancer cells. BioNTech bought it in 2020 and it became BioNTech's US base.
Neon Therapeutics was an immuno-oncology company developing neoantigen-targeted therapies that direct the immune system towards neoantigens (Third Rock Ventures). BioNTech closed its all-stock acquisition of Neon (Nasdaq: NTGN) on 6 May 2020, after announcing the agreement on 16 January 2020. The Cambridge, Massachusetts subsidiary was to operate as BioNTech US Inc. and serve as BioNTech's US headquarters.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/